Allergan signs $3.35 billion Alzheimer’s treatment deal with Heptares
7 April 2016 | By Victoria White, Digital Content Producer
Allergan is to license exclusive global rights to a broad portfolio of novel subtype-selective muscarinic receptor agonists in development by Heptares...